Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Dave Coulier, 65, announced on Tuesday that he has stage 3 non-Hodgkin lymphoma. An oncologist explains the symptoms, ...

Any new HIV prevention method is not meant to sit on the shelf but to be used by the people who need it to protect themselves ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), ...

In a new study, researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs ...

(Howard Dean, 11/13) Miami Herald: CDC Numbers Offer Good News On HIV Infections Overall But Reveal A Crisis For Latinos When the Centers for Disease Control and Prevention published data in May of ...

Researchers have created a groundbreaking antibody that combines targeting, delivery, and immune activation to treat cancer, ...

Researchers have identified a new target to treat atherosclerosis, a condition where plaque clogs arteries and causes major cardiac issues, including stroke and heart attack.

But Dr. Joseph McGowan, HIV services medical director at Northwell Health, said he hadn’t seen a noticeable decline in STI ...

In three very small studies with a total of 28 patients, opens new tab, the therapy helped improve their ability to control ...

By the time she was treated, she was almost completely paralyzed, Monje said. The treatment worked so well that her tumor ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...